Core Insights - Guangdong Province is set to enhance its traditional Chinese medicine (TCM) sector in 2026, focusing on nine key areas including digital empowerment and standardization of TCM practices [1][2] Group 1: Key Initiatives - The province will deepen comprehensive reforms in TCM and promote the establishment of a national TCM comprehensive reform demonstration zone [1] - Guangdong aims to improve TCM service capabilities through the implementation of healthcare strengthening projects [1] - A significant focus will be on integrating Western and Chinese medicine, establishing a long-term collaborative mechanism for clinical projects addressing major diseases [1] Group 2: Talent Development and Research - Guangdong plans to strengthen its TCM research and innovation framework, accelerating the transformation of research outcomes [2] - The province will initiate the selection of national TCM masters and renowned practitioners, fostering leadership and high-level talent in the TCM field [2] - A multi-tiered talent development system will be established to enhance the quality of TCM professionals [2] Group 3: Industry and Cultural Promotion - The province will promote high-quality development across the entire TCM industry chain, focusing on resource protection and source management [2] - Efforts will be made to expand the cultural influence of TCM and accelerate its international outreach [2] - The establishment of a traceability system for key TCM materials from the Lingnan region will be prioritized [2]

Core Viewpoint - A significant number of traditional Chinese medicine (TCM) products are at risk of being eliminated from the market due to new regulatory requirements that will take effect in July 2026, which mandate clearer safety information in product descriptions [3][10]. Industry Overview - The new regulations, effective from July 2023, require that any TCM product with unclear safety information (labeled as "unclear") will not be eligible for re-registration after July 1, 2026 [3][10]. - Approximately 75% of TCM products currently on the market have safety information marked as "unclear," which poses a substantial risk of elimination for these products [5][10]. Market Impact - The impending regulatory changes are expected to lead to a significant reshuffling of market shares within the TCM industry, as many companies may not be able to meet the new requirements [10][11]. - Notable products facing potential withdrawal include those with substantial sales figures, such as Longmu Bone Strengthening Granules, which is projected to exceed 1 billion yuan in retail sales in 2024 but has unclear safety information [7][10]. Regulatory Context - The regulatory changes aim to enhance the quality of TCM products rather than a blanket elimination of all products, allowing companies to submit additional research and safety reports to comply [10][12]. - The policy encourages companies to invest in research and development to clarify the efficacy and safety of their products, thereby improving the overall scientific standards of TCM [12][13]. Future Developments - Many leading TCM companies have already begun to prepare for compliance with the new regulations, with some having successfully updated their product safety information [14]. - The regulatory framework is expected to foster a more competitive environment, potentially benefiting companies that can adapt and innovate while disadvantaging those that cannot meet the new standards [11][12].

Group 1 - The core focus of Guangdong's 2026 Traditional Chinese Medicine (TCM) work conference is to enhance new advantages and create new situations in TCM development, emphasizing nine key areas of work [1] - Guangdong plans to deepen comprehensive reforms in TCM, fully promote the construction of national TCM comprehensive reform demonstration zones, and implement the first and second batches of TCM inheritance and innovation demonstration projects [1] - A significant emphasis will be placed on promoting the integration of Chinese and Western medicine, establishing a long-term collaborative mechanism, and supporting 12 national major difficult disease clinical collaboration projects [1] Group 2 - The development of high-quality TCM is linked to strengthening new productive forces and building a high-level TCM talent team, with plans to establish a TCM research and innovation matrix and accelerate the transformation of research results [2] - Guangdong will conduct a new round of selection and recommendation for national TCM masters and famous TCM practitioners, promoting the cultivation of leading talents and high-level innovative teams in the TCM sector [2] - The province aims to enhance the TCM industry and career development, strengthen source control and resource protection, and promote high-quality development across the entire industry chain [2]

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step in the internationalization and standardization of traditional Chinese medicine (TCM), providing a unified framework for the global industry [5][7]. Group 1: Standard Release and Significance - The ISO international standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" was officially released during a seminar focused on the high-quality international development of TCM [5]. - This standard establishes a comprehensive standardization system for the global broken wall Ganoderma spore powder industry, covering aspects from raw materials to production processes and quality control [7]. - The standard sets a minimum requirement of ≥95% wall-breaking rate and introduces a multi-index evaluation system for active components, ensuring both traditional practices and modern technology are integrated [7]. Group 2: Impact on Consumers and Industry - For consumers, the standard provides a more reliable product guarantee, enabling better assessment of product safety and effectiveness, and helping to distinguish genuine products from counterfeits [7]. - The company, Shouxiangu, has been a key player in TCM standardization, having led or participated in the formulation of over 100 TCM standards, including 8 international standards [7][8]. Group 3: Future Directions and Challenges - The standardization initiative is expected to drive the internationalization of TCM, with a focus on quality and safety, while also addressing the unique challenges posed by the traditional practices of TCM [9][10]. - Experts emphasize the need for a balance between standardization and the unique characteristics of TCM, advocating for a system that integrates traditional wisdom with modern scientific approaches [10][11]. - The seminar highlighted the importance of protecting authentic medicinal materials and educating international markets as key factors in promoting the internationalization of TCM [11].

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step towards the internationalization of traditional Chinese medicine (TCM), providing a unified framework for quality and safety in the global market [4][6]. Group 1: Standard Release and Significance - The ISO standard (ISO/TS 25006:2025) for Broken Wall Ganoderma Spore Powder was officially released, establishing a comprehensive standardization system from raw materials to production and testing [4][5]. - This standard serves as a "world language" for TCM, facilitating the internationalization of Zhejiang-produced traditional medicine [4][6]. Group 2: Production and Quality Control - The standard specifies raw material sourcing requirements and sets a critical parameter of ≥95% wall-breaking rate, ensuring standardized production control [5]. - It introduces a fingerprinting multi-index evaluation system for active components, balancing traditional practices with modern technology [6]. Group 3: Consumer Impact and Industry Leadership - For consumers, the standard enhances product reliability, enabling better assessment of safety and efficacy, and helping to distinguish quality products [6]. - The company, Shouxiangu, has led the development of over 100 TCM standards, including 8 international standards, contributing to the global recognition of TCM [6][7]. Group 4: Challenges and Innovations in TCM - The implementation of the standard addresses a global quality gap in TCM and injects new momentum into the internationalization of the industry [7]. - Experts emphasize the need for a balance between traditional TCM practices and modern standardization requirements, highlighting the challenges posed by differing legal and cultural contexts [7][8]. Group 5: Future Directions - The company aims to continue its efforts in international standard formulation, promoting more Zhejiang-produced medicinal materials globally and enhancing cooperation with countries along the "Belt and Road" initiative [6][8]. - The conference signifies a new phase in TCM internationalization, focusing on standard leadership, industry collaboration, and global sharing [8].

Core Viewpoint - The release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the standardization of traditional Chinese medicine (TCM), promoting quality and international development in the industry [1][2][4]. Group 1: Standardization and Innovation - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" will be implemented in July 2025, following previous standards for other TCM products [2]. - The standard establishes key parameters such as raw material sources, a minimum 95% breaking rate, and a multi-index quality control system, enhancing production technology standardization [4]. - Experts emphasize that TCM standardization is a process of deriving scientific rules from clinical practices to form internationally recognized standards [4]. Group 2: Economic Impact - The implementation of ISO standards has led to significant increases in international trade, with related products seeing trade growth of 284.5% and 37.5% for Ganoderma and Dendrobium, respectively [5]. - The standards have been adopted in 31 countries, including major markets like the US, Canada, Australia, and Germany, facilitating trade recognition [5]. Group 3: International Collaboration - Collaborations with international institutions, such as clinical research on TCM's anti-tumor effects and cardiovascular benefits, are enhancing the scientific basis for standardization [6]. - The Zhejiang provincial government plans to strengthen the internationalization of TCM standards, focusing on local medicinal materials and specialty TCM products [6]. Group 4: Future Directions - The establishment of a comprehensive standard system covering the entire industry chain, from cultivation to clinical evaluation, is seen as essential for enhancing the industry's competitiveness [7]. - The company aims to deepen international standard formulation and promote local medicinal materials globally, particularly in countries along the Belt and Road Initiative [9].

Core Viewpoint - The number of national standards for traditional Chinese medicine (TCM) has significantly increased during the 14th Five-Year Plan period, with a focus on expanding coverage and advancing internationalization [1] Group 1: Growth of National Standards - During the 14th Five-Year Plan period, the National TCM Standardization Technical Committee has promoted the release of 34 national standards, accounting for 65.4% of the TCM national standards published during the same period [1] - The total number of TCM national standards has reached 36 [1] Group 2: Development of Standard System - The National TCM Standardization Technical Committee has established and improved the TCM national standard system framework, covering clinical TCM, basic TCM, ethnic medicine, and TCM information [1] - The committee has initiated pilot studies on the clinical specialty standard system and has pushed for the establishment of 19 foreign language versions of national standards, covering important aspects such as TCM diagnostic techniques and clinical terminology [1] Group 3: Role of the National TCM Standardization Technical Committee - The National TCM Standardization Technical Committee, established by the National Administration of Traditional Chinese Medicine, is responsible for proposing guidelines, policies, and technical measures for TCM standardization [1] - The committee organizes the formulation, revision, review, publication, promotion, and dissemination of TCM national standards [1]

Group 1 - The core viewpoint of the articles highlights Hong Kong's efforts to establish a robust framework for Traditional Chinese Medicine (TCM) to enhance its global presence and acceptance [1][2][3] Group 2 - Hong Kong has developed a regulatory system for TCM, including the establishment of the Hong Kong Chinese Medicine Standards and a Chinese Medicine Testing Center, which will begin phased operations in December 2025 [1] - The Hong Kong government has invested a total of 1 billion HKD in the Chinese Medicine Development Fund since 2019, supporting over 10 funding programs in training, research, public awareness, industry development, and quality enhancement [2] - As of November 2025, there are 10,842 registered Chinese medicine practitioners in Hong Kong, with over 90% practicing in the community, creating a strong grassroots healthcare network [2] Group 3 - The Hong Kong Chinese Medicine Hospital, set to begin phased services in December 2025, aims to promote TCM education, training, and research innovation, supporting clinical research and the development of Chinese patent medicines [2] - The TCM industry in Hong Kong actively organizes promotional activities, with government support for projects that enhance public understanding and recognition of TCM [2][3]

Core Viewpoint - The National Healthcare Security Administration has revised the coding rules for traditional Chinese medicine (TCM) decoction pieces, introducing new identifiers to enhance traceability and transparency in the industry [1]. Group 1: Coding Revisions - The revision does not significantly alter the existing coding structure but adds two key segments: the "Authentic Medicinal Material Identifier" and the "Decoction Piece Enterprise Code" [1]. - The "Authentic Medicinal Material Identifier" serves as a geographical certification label for decoction pieces, making information about authentic varieties like Yunnan Sanqi and Sichuan Chuanbei clear [1]. - The "Decoction Piece Enterprise Code" accurately links to the producing enterprises, ensuring traceability and accountability [1]. Group 2: Industry Impact - The new coding segments fill a long-standing information gap regarding the authenticity and production of decoction pieces, thereby enhancing product transparency [1]. - The coding provides each decoction piece with a unique healthcare "identity," applicable in billing, reimbursement audits, and fund supervision, which helps enforce corporate responsibility [1]. - The current database includes over ten thousand decoction piece codes, covering more than 3,000 types of medicinal materials and 22 categories of efficacy, achieving a "national unified code" [1].

Core Viewpoint - The 22nd China International Health Expo highlighted the achievements of Zhejiang Shouxiangu Pharmaceutical Co., Ltd., recognized as a leading enterprise in the health industry, showcasing its innovations in the Ganoderma lucidum sector and its commitment to traditional Chinese medicine and technological advancement [2][5]. Group 1: Company Achievements - Shouxiangu has established the world's largest Ganoderma lucidum germplasm resource bank, preserving over 13,388 varieties since the 1990s [3]. - The company developed the first domestically approved Ganoderma lucidum variety "XianZhi No. 1" in 2001, breaking the reliance on imports from Japan and South Korea [3]. - Shouxiangu has built over 10,000 acres of organic medicinal herb cultivation bases, achieving various organic certifications from China, the EU, the US, Japan, and Canada [3]. Group 2: Technological Innovations - The company has independently developed the third-generation wall-breaking technology for Ganoderma lucidum spore powder, significantly enhancing the effective ingredient content by over 10 times and improving absorption rates by an average of 29 times compared to regular wall-breaking spore powder [3]. - Shouxiangu has been recognized with a gold medal at the 46th Geneva International Exhibition of Inventions for its technological breakthroughs [3]. Group 3: Standardization and Digital Transformation - Since 2006, Shouxiangu has undertaken the development of over 100 international, national, and industry standards, including ISO standards for Ganoderma lucidum and other medicinal herbs [4]. - The company is set to implement new ISO standards for "White Atractylodes" and "Wall-Breaking Ganoderma lucidum spore powder" in July 2024 and July 2025, respectively, enhancing China's international influence in traditional medicine [4]. - Shouxiangu is advancing digital transformation by creating a collaborative application system across the entire industry chain, including smart farms and factories, which has led to a 50%-80% increase in medicinal herb yield and a 35% improvement in effective ingredient stability [4]. Group 4: Product Offerings and Cultural Heritage - At the expo, Shouxiangu showcased its core product lines, including Ganoderma lucidum, Dendrobium, and saffron, covering traditional Chinese medicine products, health foods, and herbal daily necessities [5]. - The company also presented its national intangible cultural heritage techniques for traditional Chinese medicine processing, emphasizing its commitment to cultural preservation alongside technological innovation [5].